Abstract
BACKGROUND:
there are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications.
METHOD:
Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as part of multidrug therapy. We selected a control group of 187 healthy pregnant women.
RESULTS:
topical use of timolol alone or timolol in combination with other antiglaucoma medications don't influence pregnancy or fetal/neonatal outcomes.
CONCLUSION:
beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.
Lingua originale | English |
---|---|
pagine (da-a) | 3-11 |
Rivista | Current Drug Safety |
Volume | 13 |
DOI | |
Stato di pubblicazione | Pubblicato - 2018 |
Keywords
- pregnancy, glaucoma, congenital malformations, teratology, eye